DENTSPLY SIRONA (NASDAQ:XRAY) Director Gregory Lucier Acquires 15,000 Shares

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory Lucier bought 15,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was purchased at an average cost of $12.45 per share, with a total value of $186,750.00. Following the completion of the acquisition, the director directly owned 65,000 shares of the company’s stock, valued at approximately $809,250. The trade was a 30.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

DENTSPLY SIRONA Stock Up 0.5%

Shares of NASDAQ:XRAY traded up $0.06 during trading on Monday, reaching $12.80. 3,590,550 shares of the stock traded hands, compared to its average volume of 4,989,556. The stock has a market cap of $2.56 billion, a P/E ratio of -4.27, a price-to-earnings-growth ratio of 1.49 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The stock has a 50-day moving average of $12.63 and a two-hundred day moving average of $12.45. DENTSPLY SIRONA Inc. has a 52-week low of $9.85 and a 52-week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. During the same period last year, the company posted $0.26 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $0.64 annualized dividend and a dividend yield of 5.0%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -21.33%.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Wells Fargo & Company lifted their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Barclays started coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They set an “underweight” rating and a $12.00 price target on the stock. Finally, Barrington Research raised their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA currently has an average rating of “Hold” and a consensus price target of $14.42.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA during the first quarter valued at about $26,000. Goldman Sachs Group Inc. raised its stake in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after buying an additional 2,172,343 shares during the period. Empowered Funds LLC lifted its position in shares of DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after buying an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after acquiring an additional 41,579 shares during the period. Finally, Focus Partners Wealth grew its stake in shares of DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 9,355 shares during the period. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.